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The ABO blood group system includes phenotypes, or subgroups, 
that differ in the amount of A and B antigens present on the red 
blood cells (RBCs). These subgroups also differ in the A, B, or 
H substances present in secretions (for individuals who have 
the secretor phenotype). B subgroups are very rare and are less 
frequently reported than A subgroups. Usually, B subgroups are 
discovered during serologic testing when there is a discrepancy 
between RBC and serum grouping results. Subgroups of B are 
usually identified by a reference laboratory using molecular and 
adsorption-elution methods. This report details a case of a young, 
healthy, pregnant woman with a B subgroup detected by a small 
transfusion service using adsorption-elution methods. Serology 
and genotyping of the ABO gene was performed at a reference 
laboratory where the serology was consistent with a B subgroup, 
but no changes were identified in ABO gene sequencing. It is 
important to correctly identify B subgroups in donors and 
recipients to help resolve ABO discrepancies and potentially pre-
vent ABO incompatibility in blood transfusion, thus minimizing 
transfusion reactions. Immunohematology 2021;37:89–94. 
DOI:10.21307/immunohematology-2021-0014.
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The ABO blood group system is the most clinically 
significant antigen system in transfusion medicine. The 
ABO gene is located on chromosome 9 and consists of seven 
exons. Exons 6 and 7 encode for the catalytic domain of the 
ABO glycosyltransferases. The A blood group is formed by 
the addition of N-acetyl-galactosamine to the H antigen, the 
B blood group is formed by the addition of galactose to the H 
antigen, and blood group O results when no sugar is added 
to the H antigen.1 ABO blood groups have subgroups that are 
often distinguished by decreased amounts of A or B antigens 
on red blood cells (RBCs). A and B subgroup phenotypes 
can be identified based on the quantity of A or B antigens 
carried on RBCs and A or B substances present in secretions 
(for individuals who have the secretor phenotype). The most 
common subgroups are A1 and A2 (in Europeans, 80% of all 
group A and AB individuals are A1 and 20% are A2).2 Blood 
group A appears to have more subgroup variations than group 
B. In general, the serologic distinction between A1 and other 
subgroups of A is based on the ability of anti-A1 lectin (an extract 
of Dolichos biflorus seeds) to agglutinate A1 RBCs but not 
RBCs of other A subgroups.2 There are no comparable B1 and 
B2 subgroups, but examples of group B RBCs that react weakly 
or not at all with anti-B have been described.3 B subgroups 
are very rare and are less frequently reported.3 Usually, B 
subgroups are discovered during serologic testing when there 
is a discrepant result between RBC and serum grouping tests. 
Subgroups of B are difficult to classify and include B3, Bx/Bweak 
(previously known as Bx), Bweak (previously known as Bm), 
and Bel phenotypes, according to the International Society of 
Blood Transfusion (ISBT).4,5 The B subgroups can be classified 
by their agglutination strength with anti-B, anti-A,B, and 
anti-H; the presence or absence of anti-B in the serum; the 
presence of B substance in saliva; the results of adsorption-
elution testing; and molecular studies (Table 1).2,6 An up-to-
date listing of molecular variants recognized by ISBT that 
give rise to the observed serologic phenotypes can be found 
on their Web site in the table for ABO (ISBT 001) blood group 
alleles v1.2.4 Definitive identification of ABO subgroups is 
usually performed at a reference laboratory using molecular 
and adsorption-elution methods, which often have long 
turnaround times.
Case Report
Here we report a case in which a B subgroup was 
detected by an observant technologist using both automated 
gel and manual tube methods with conventional reagents 
at a busy hospital transfusion service. The facility is a 450-
bed, small, community hospital and level 1 trauma center. 
The hospital transfuses an average of 5500–6000 total units 
of blood components annually. The lab received an EDTA-
anticoagulated blood specimen for a type and screen order 
from a young healthy pregnant woman. Discrepant results 
(forward as group O and reverse as group B) were observed 
while performing routine blood ABO testing by the gel method 
(see Methods and Results). Repeat testing by a conventional 
tube method showed the same discrepancy. This 29-year-
old African American woman presented to an obstetric clinic 
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for routine prenatal care at 28 weeks, 4 days, gestational 
period for Rh(D) determination for possible Rh immune 
globulin (RhIG) administration. At the time of this visit, the 
patient had no previous history of transfusion, pregnancies, 
or transplantation, with current diagnosis of nonimmune, 
mild anemia, and a history of varicella. Her hemoglobin and 
hematocrit were 10.3 g/dL (normal range 11.9–16.0 g/dL) and 
29.7 percent (normal range 35–47%), respectively. No blood 
transfusion was needed at this time. Her RBCs were typed 
as D–, and she received RhIG during this visit. The patient 
had previously tested as group O, D– with a negative antibody 
detection test at two other hospitals for the same pregnancy, 
including her most recent visit 1 month prior. About 3 months 
later, the patient had a spontaneous vaginal delivery with no 
transfusion demands. Postpartum RhIG was administered to 
her in a timely manner.
Methods and Results
Serologic-based ABO phenotypes were determined by 
agglutination and adsorption-elution testing according to 
standard methods and procedures described in the AABB 
Technical Manual.1 Discrepant results (forward as group O and 
reverse as group B) were observed while performing routine 
blood grouping on an automated gel-method analyzer (ORTHO 
VISION; Ortho Clinical Diagnostics, Raritan, NJ); antibody 
detection test results were negative. An attempt to resolve the 
discrepancy observed on the automated gel analyzer led the 
technologist to repeat testing using the conventional manual 
tube method, which showed the same discrepancy.
The manual tube method demonstrated no agglutination 
with the patient’s RBCs and blood grouping reagents (Ortho 
Clinical Diagnostics), including anti-A, anti-B, and anti-A,B 
(BioClone [Murine Monoclonal Blend], San Diego, CA) at 
immediate spin, or after 30 minutes at room temperature, but 
weak reactivity was noted with anti-B and anti-A,B at 4°C. The 
patient’s serum showed the presence of a strong anti-A, but 
no anti-B was detected using pooled RBCs (AFFIRMAGEN; 
Ortho Clinical Diagnostics) (Table 2).
Although decreased expression of A and B antigens has 
been observed in patients with hematologic malignancies, our 
patient was a healthy young woman, suggesting the possibility 
that the discrepant ABO typing results were due to a weak B 
subgroup. To explore the possibility of a B subgroup, direct 
antiglobulin tests (DATs) were first performed by conventional 
tube method with anti-IgG (Rabbit; Ortho Clinical Diagnostics) 
and anti-C3b/-C3d (Murine Monoclonal; BioClone, Ortho 
Clinical Diagnostics) reagents; all DAT results were negative. 
Table 1. Characteristics of some more frequent B phenotypes
Reagents Antibodies in serum Other
Phenotypes Anti-A Anti-B Anti-A,B Anti-H Common Unexpected
Substances present in  
saliva of secretors
Presence of a B transferase  
in serum
B 0 4+ 4+ 2+ Anti-A None B, H Yes
B3 0 ++mf ++mf 3+ Anti-A None B, H Yes (wk pos)
Bx 0 wk wk 3+ Anti-A Weak anti-B H No
Bm* 0 0/wk 0/wk 3+ Anti-A None B, H Yes (wk pos)




*B specificity demonstrated only by adsorption-elution methods.
0 = negative; mf = mixed field; wk = weak; pos = positive.
Table 2. Results of forward and reverse grouping and antibody detection tests
RBCs with reagent Serum with reagent
Autocontrol
Antibody detection test 
(gel method)Anti-A Anti-B Anti-A,B A1 RBCs B RBCs
IS RT 0 0 0 4+ 0 0
30 minutes RT 0 0 0 4+ 0 0 Negative
4°C 0 W+ W+ 4+ 0 0
RBCs = red blood cells; IS = immediate spin; RT = room temperature; W+ = weak reaction.
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After ensuring that the patient’s RBCs were not coated with 
IgG and/or C3b/C3d by the DAT, adsorption was performed 
using washed patient RBCs and reagent anti-B (BioClone, 
Murine Monoclonal Blend; Ortho Clinical Diagnostics).1 After 
1-hour incubation at 4°C, an acid elution was performed. 
The eluate and final wash supernatant were tested in parallel 
against A1 and B reagent RBCs (AFFIRMAGEN), and three 
group O reagent antibody screening RBCs (SURGISCREEN; 
Ortho Clinical Diagnostics). The eluate reacted only with group 
B RBCs when incubated at 37°C for 15 minutes and tested 
using the indirect antiglobulin test (Table 3).1 Because the 
patient’s saliva was not available for secretor testing, whether 
the patient has a Bweak or Bel phenotype remains unknown.
Since the absorption-elution results were consistent with a 
weak B subgroup, the patient’s specimen was sent to a reference 
laboratory for further evaluation. The reference laboratory’s 
serologic testing confirmed the discrepant forward and reverse 
results. Initial molecular testing revealed no changes in ABO 
exons 6 and 7 known to explain the discrepancy. Full sequenc-
ing of the ABO gene exons 1–7 of the A and B transferase genes 
was performed using Sanger DNA sequencing technology. 
The polymerase chain reaction (PCR) restriction fragment–
length polymorphism (RFLP) was performed for nucleotide 
positions c.261(O1), c.467(A2), c.703(B), and c.1065+31 (B and 
O2). The PCR-RFLP testing indicated the presence of c.703A 
and c.1065+31A, characteristic of B alleles, and c.261delG, 
characteristic of O 1 alleles. The genomic sequencing of 
exons 1–7 showed the presence of an O 1 allele, specifically 
ABO*O.01.09 (c.261delG, c.318T, and c.467T), on exon 6 and 
confirmed the presence of a B allele, specifically ABO*B.01 
(c.297G, c.526G, c.657T, c.703A, c.796A, c.803C, and c.930A), 
on exons 6 and 7. The patient was heterozygous for each of 
the variants found. No other changes were found in exons 
1–5. The reference laboratory concluded that the patient was 
ABO*B.01/ABO*O.01.09 with a predicted phenotype of a weak 
B subgroup. Additional investigation was recommended. 
Discussion
This case showed that conventional serologic testing can be 
used to detect a weak B subgroup. The detection of weak ABO 
subgroups is very important in clinical settings, as well as in 
blood donor centers, because a person with weak B expression 
may be wrongly typed as group O when anti-B is present in the 
patient/donor plasma. Rare hemolytic transfusion reactions 
(HTRs) due to ABO incompatibility involving ABO subgroups 
have been reported. As Chun et al.7 reported, a patient with 
cis-A1B3 interpreted as typical group A experienced adverse 
effects after transfusion of 4 units of group A RBCs and 4 
units of group A fresh frozen plasma (FFP). Although reaction 
between the B antigen of the cis-AB patient and anti-B from 
the group A FFP is theoretically possible, the authors could 
not draw a definitive conclusion for the cause of hemolysis.7 
To our knowledge, an HTR involving B subgroup has not been 
reported.
Theoretically, an HTR (perhaps with mild clinical 
effects or shortened RBC survival due to lower-level antigen 
expression on the patient’s RBCs) may happen in transfusions 
involving ABO subgroups, such as when a B subgroup recipient 
mistyped as group O is transfused with a group O plasma–
containing blood component, or a RBC unit from a donor 
with weak B subgroup mislabeled as group O is transfused to 
a group O recipient. Chaurasia et al.8 emphasized that when 
individuals with B subgroups present as transfusion recipients, 
they should be transfused with group O RBC components 
and group B–specific plasma and platelet components. These 
authors report that RBCs from B subgroup donors transfused 
to group O recipients can result in an adverse HTR.8
In the United States, as required for pre-transfusion testing 
by the AABB Standards for Blood Banks and Transfusion 
Services, the ABO group shall be determined by testing RBCs 
with anti-A and anti-B reagents and by testing the serum or 
plasma for expected antibodies with A and B reagent RBCs. If 
a discrepancy is detected and transfusion is necessary before 
resolution, only group O RBCs shall be issued.1
This type of serologic discrepancy, with decreased 
expression of A or B antigens on RBCs, can be observed in 
acquired ABO subgroup phenotypes such as seen in infants, 
individuals with hematologic disorders, and pregnant 
women;9 however, our patient was healthy, and, although 
pregnant, had typed as group O in two hospitals she visited 
previously. These reported results indicate that anti-B was 
presumably detected in her plasma, although this information 
was not confirmed with the testing facilities. The technologist 
Table 3. Adsorption-elution results
Reagent RBCs A1 RBCs B RBCs
O cells*
Cell I Cell II Cell III
Eluate 0 2+ 0 0 0
Last wash 0 0 0 0 0
*Reagent antibody screening red blood cells (RBCs).
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at our transfusion service was able to “dig deep” into this 
case and used serologic investigation to discover a weak B 
subgroup. The reference laboratory’s serology tests confirmed 
this finding. The detection of a B subgroup is important to 
prevent potential ABO-mismatched transfusion reactions. 
Weak B subgroups are rarely detected in a hospital transfusion 
service setting. The ability to confirm a weak ABO subgroup 
phenotype generally requires molecular testing. DNA-based 
tests are increasingly being used at immunohematology 
reference laboratories to predict blood group phenotype, which 
helps to improve transfusion medicine practices.10,11 Reference 
laboratories use several methods for genotyping, including 
PCR followed by RFLP analysis, sequence-specific primer 
PCR, DNA sequencing, and array-based approaches.11 A 
notable advantage of molecular testing is its ability to identify 
variant alleles associated with antigens that are expressed 
weakly or have missing or altered epitopes, thus helping to 
resolve discrepant or incomplete blood group phenotyping.12 
The disadvantages of molecular testing are mainly the longer 
turnaround time (days to weeks11) and higher cost, compared 
with serologic typing.
In our patient’s case, full ABO gene sequencing did not 
identify any changes in the B allele that would explain the 
undetectable B antigen expression, raising the possibility that 
the patient may have a gene regulator or a promoter mutation 
in the non-coding regions of the B allele. Given that most weak 
B phenotypes are due to random missense mutations in the last 
ABO exon,13 the failure to identify a mutation makes this case 
somewhat unusual. Nevertheless, uncommon novel mutations 
are increasingly identified given the widespread availability of 
molecular testing, and mutations outside of the coding region 
are not uncommon.
Huang et al.13 reported the analysis of 1.4 million Chinese 
blood donors; 351 cases of weak ABO subgroups were 
identified serologically. In the 326 samples subject to DNA 
analysis, 44 ABO mutations were identified, of which only 
10 were novel. No mutations were observed in 99 samples. A 
similar recent analysis of 211 ABO subgroups in Chinese blood 
donors detected by discrepant serologic typing revealed that 36 
samples (approximately 17%) including four pregnant donors 
had discrepant results that were not explained by underlying 
disease or initial sequencing and may have an unexplained 
molecular basis.14 Mutations leading to weak subgroups may 
also occur in areas outside the coding region of the ABO gene. 
Seltsam et al.15 reported that weak B phenotypes can be caused 
by sequence variation in the CCATT-binding factor (CBF)/ 
NF-Y region of the ABO gene, and Thuresson et al.16 described 
a hybrid between an O 2 and a B allele and characterized the 
associated decrease in B antigen expression. Sano et al.17 
identified a positive regulatory element in intron 1. This 
element was shown to enhance ABO promoter activity in an 
erythroid cell–specific manner, and a partial deletion in intron 
1 involving the erythroid cell–specific regulatory element 
was associated with Bm phenotypes. The authors suggested 
that deletion of this enhancer-like element in intron 1 of ABO 
regulates transcription in the Bm allele, leading to reduction 
of B antigen expression on cells of erythroid lineage, but not 
in mucus-secreting cells.17 In the study of Ying et al.,14 75 
samples of ABO variants were considered to have an unclear 
molecular basis, because only normal sequences were detected 
in their ABO coding regions. Among these samples, 32 were 
from individuals with infection, hematologic disorders, and 
other diseases. For the remaining 43 individuals with ABO 
subgroups, seven were associated with the erythroid cell–
specific regulatory element in the first intron of the ABO gene14 
based on the analysis of the nucleotide sequences of the partial 
intron 1 covering this +5.8-kb region. The other 36 samples 
in this group obtained from apparently healthy individuals 
(including four from pregnant women) might have an unclear 
molecular basis.14
For the B subgroup patient in this case, our reference 
laboratory suggested that further investigation would be 
conducted. Most hospital transfusion service laboratories do 
not perform molecular-based testing. They are usually capable 
of serologic testing to identify A1 and A2, the most common 
A subgroups, but can recognize the possibility of weaker 
subgroups of A or B by characteristic discrepancies between 
RBC and plasma grouping tests.3 Hospital transfusion service 
laboratories rarely conduct a serologic investigation to detect 
weak B subgroup. This case, however, demonstrated that 
conventional serologic testing can be used to detect a weak B 
subgroup. The approach for detection of a weak B subgroup 
in the hospital laboratory setting is particularly useful when 
access to molecular-based reference laboratory testing is 
limited or if the patient needs urgent blood transfusion. 
The much lower cost and faster turnaround time of the 
conventional serology tests, in comparison to molecular-based 
genotyping tests, offer advantages. Serologic testing has been 
used elsewhere to identify and characterize ABO subgroups in 
a large group of blood donors and patients18 and B subgroups 
in a group of three patients and donors.19
B subgroup should be suspected when serologic testing 
results show a discrepancy of forward as group O and reverse 
as group B, with a negative antibody detection test at immediate 
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spin. B subgroup phenotype can then be determined by using 
adsorption-elution testing, secretor testing for B substance, 
and serologic classification discussed in this report.6 Guidelines 
exist and are summarized in Table 1.2
Individuals with some B subgroups, such as Bx/Bweak and 
Bel, can produce anti-B. Transfusion of group O RBCs and 
group B plasma–containing components to these individuals 
can address this type of B subgroup incompatibility due to 
anti-B to prevent an HTR. In our opinion, it is not clinically 
necessary to further differentiate between Bweak or Bel subgroups 
in these recipients. For this young healthy woman in our case 
with B subgroup but without identified variant alleles, further 
research could be conducted on the non-coding regulatory 
elements, such as PCR amplification and sequencing for the 
5.8-kb enhancer region in the intron 1 enhancer region, and 
on the sequence variation in the (CBF)/NF-Y enhancer region 
of the ABO gene. However, it is possible that the patient’s 
pregnancy caused the B subgroup phenotype, with other 
unknown or no molecular subgroup basis. Identification 
of the patient’s B subgroup may help to prevent potential 
ABO incompatibility, if the patient needs blood transfusion. 
Nevertheless, further investigation to determine the molecular 
basis of the patient’s B subgroup phenotype at this small 
community hospital transfusion service is neither feasible nor 
necessary.
Conclusion
The hospital transfusion service identified, in a timely 
manner, a B subgroup using conventional serologic methods; 
these methods had the potential of preventing an ABO-
mismatch transfusion reaction. This approach is also 
particularly useful when molecular testing by reference 
laboratory resources is limited or if the patient’s urgent need 
of blood transfusion cannot wait for the reference laboratory’s 
results. Nevertheless, the serologic testing approach to detect 
the weak B subgroup often requires a confirmation by genomic 
analysis because this information is crucial to donor centers 
and transfusion services.
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